The U.S. Food and Drug Administration announced that they are launching an initiative to spare dogs from veterinary drug trials. The new FDA project is specifically aimed at the so-called “bioequivalence trials” where the researchers try to verify if a new type of drug has the same effect as an already existing one. The FDA wants to spare dogs in future veterinary trials.
The problem with these trials is that at the end of the trial, these dogs need to be euthanized so they can do a necropsy on them and see what effects the drug had on its internal organs and tissues.
FDA Commissioner Gottlieb says that they are trying to put these trials in the past and to introduce a new way of testing drugs on dogs, with a minimally invasive blood sampling only.
Also, he says that a whole team is working with the dogs before, during and after the trials because the end goal is to find forever homes for these dogs. That is why they need to be socialized and well behaved.
One example of the new standard is an antiparasitic drug testing. Before, after the administration of the drugs, the dogs were euthanized and then examined to see if there were parasites in the intestines and what kind of damage was done to the intestinal walls.
Now, the dogs will receive 3 doses of the antiparasitic pill and then have their blood drawn so the researchers can see if the concentration of the drug is on a same or similar level as already commercially available drugs.
Read the original story “FDA hopes to spare dogs in veterinary drug trials”.
If you liked this article, read “Most common internal parasites in dogs and cats” on our blog.